Intellectual Property
We recognize the significant investment our clients make in developing their products and technologies. Our nationwide team of intellectual property attorneys is dedicated to safeguarding these innovations with strategic and incisive legal counsel. Whether advising on global product launches or handling multibillion-dollar patent litigation, we are committed to protecting IP rights and fueling business growth.
Leading High-Stakes Trials & Appeals
Our first-chair trial lawyers bring extensive experience in all phases of patent and trade secret litigation, including at trial and on appeal. We have led some of the most high-profile cases in federal and state courts nationwide and regularly advocate for our clients before the International Trade Commission (ITC) and Patent Trial and Appeal Board (PTAB).
When our clients’ patent rights are violated or challenged, we mobilize our nationwide team of trial attorneys to advocate for their innovations in court. Over the past decade, we have tried more than 250 cases in federal and state courts, as well as before the ITC, PTAB, and United States Court of Appeals for the Federal Circuit (CAFC).
Clients frequently call on us to assume lead trial counsel roles in high-stakes litigation, especially when the legal or factual circumstances are not in their favor. Our ability to develop creative solutions and compelling arguments has earned us a strong track record in precedent-setting cases.
We defend our clients’ interests in the highly competitive pharmaceutical, biotechnology, and medical device industries, having served as lead trial counsel in hundreds of abbreviated new drug application (ANDA) cases over the past decade.
Advising both branded and generic drug companies, we represent clients in Hatch-Waxman and ANDA litigation, as well as on patent and noticing provisions related to the Biologics Price Competition and Innovation Act (BPCIA).
Our counseling services include pre-litigation strategies and guidance on inter partes review (IPR) petitions to assist in the selection, development, approval, and marketing of pharmaceuticals, technologies, and therapies.
As manufacturers navigate an evolving regulatory landscape, they need legal counsel with deep experience before the FDA to secure market entry and protect marketing exclusivity rights.
We advise clients throughout the entire product life cycle – from development and approval to marketing – across a wide range of FDA-regulated products, including brand and generic drugs, biologics, biosimilars, human tissue and stem cell products, medical devices, food, and dietary supplements. Our team also represents clients in patent licensing and antitrust-related FDA disputes.
Our experienced IP trial attorneys are well versed in the complexities of ITC Section 337 investigations, having appeared in dozens of investigations and received remedial orders for Complainants and findings of No Violation for Respondents.
We have a strong track record representing clients in high-profile cases across industries such as mobile devices, semiconductors, and chemical compounds. Our team combines years of legal and technical expertise to navigate these fast-paced cases, leveraging a deep understanding of ITC procedures.
- UMTS and LTE Cellular Communication Modules and Products Containing Same. Represented Respondent and received a finding of no violation based on noninfringement and invalidity of all four patents involving UMTS/LTE standards asserted against mobile communication modules.
- Casual Footwear and Packaging. Represented Respondent Hobby Lobby against allegations of trade dress infringement at the ITC. The Initial Determination found Hobby Lobby did not infringe and that the trade dress was invalid, resulting in a finding of no violation. The Commission affirmed no violation based on non-infringement.
- Multi-venue Dispute. Represented numerous clients in a combination of ITC investigations, district court litigations, and IPRs, resulting in several victories later affirmed by the Federal Circuit.
Meet the Team Thought Leadership Commission Research Resource
Since the United States Patent and Trademark Office (USPTO) established the current regime of post-grant proceedings in 2012, our attorneys have secured numerous favorable outcomes for our clients. Many of our attorneys are registered to practice before the USPTO, hold advanced technical degrees, and collectively have litigated hundreds of inter partes review (“IPR”), covered business method (“CBM”), and post-grant review (“PGR”) proceedings.
As petitioner’s counsel, we strategically file IPR petitions to take an offensive approach to defending our clients. As Patent Owner’s counsel, we use our litigation skills to defend the property right. And we follow up our PTAB results by defending them on appeal, so that our clients need not retain new counsel unfamiliar with the proceedings before the PTAB.
When trade secret misappropriation disputes arise, our experienced trial team employs aggressive litigation strategies to assert or defend claims in state and federal court, and before the ITC.
In instances of theft, we deliver a rapid, decisive response to mitigate damage, recover losses, and secure emergency remedies like restraining orders and injunctions. On the defense, we proactively challenge broad accusations, focusing on whether the information is truly secret and adequately protected.
Prevention is essential for protecting corporate trade secrets. In advance of disputes, we collaborate with clients to develop and implement safeguards that minimize risk and prevent litigation.
Featured Insights
Featured Insights
CompLaw Antitrust West Coast Conference 2025
Speaking Engagement
Antitrust
ABA 73rd Annual Section of Antitrust Law Spring Meeting
Speaking Engagement
Antitrust
AIPLA CLE Web Series: Hot Topics in Chemical & Biotech Patent Practice
Speaking Engagement
17th Annual Practitioners' Think Tank on ITC Litigation & Enforcement
Speaking Engagement
Intellectual Property
Antitrust Enforcement Trends and Policies in 2025: Unfair Competition, Merger Policies, Premerger Procedures
Webinar
Antitrust
CompLaw Nordic 2025
Speaking Engagement
Antitrust
Kenina Lee Selected as a Member of Law360's 2025 Editorial Advisory Board
Awards & Recognitions
Antitrust
In U.S. FTC’s GTCR Case, Focus on PE Rollups Takes Back Seat to Traditional M&A Review
Media Mentions
Antitrust
IP Litigator Joseph Micallef Joins Axinn in Washington, D.C.
News
Intellectual Property
Veteran IP Atty Joins Axinn's D.C. Office as Partner From Sidley
Media Mentions
Intellectual Property